Nargiza Aliev, NP
Family · Frisco, TXNPI 1205358348
Payments from drug & device makers
Across 276 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$562
- Mannkind Corporation$420
- Abbott$396
- Lilly USA, LLC$371
- Xeris Pharmaceuticals, Inc.$217
- IBSA Pharma Inc.$197
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,24797%
- Gifts$591%
- Other$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $562 |
| Mannkind Corporation | 35 | $420 |
| Abbott | 33 | $396 |
| Lilly USA, LLC | 27 | $371 |
| Xeris Pharmaceuticals, Inc. | 12 | $217 |
| IBSA Pharma Inc. | 12 | $197 |
| Boehringer Ingelheim | 11 | $187 |
| Insulet Corporation | 9 | $172 |
| Dexcom, Inc. | 9 | $159 |
| Medtronic | 8 | $137 |
| Amneal Pharmaceuticals LLC | 8 | $136 |
| Corcept Therapeutics | 7 | $126 |
| Amgen | 6 | $124 |
| Recordati_rare_diseases_inc. | 6 | $120 |
| Sanofi-aventis U.S. LLC | 6 | $119 |
| BETA Bionics, Inc. | 7 | $109 |
| Tolmar, Inc. | 5 | $89 |
| Antares Pharma, Inc. | 5 | $86 |
| Tandem Diabetes Care, Inc. | 5 | $83 |
| Halozyme Inc | 4 | $70 |
| AbbVie | 3 | $57 |
| Radius Health, Inc. | 3 | $54 |
| Alvogen Inc | 3 | $52 |
| Soleno Therapeutics, Inc. | 2 | $47 |
| Cequr Corporation | 1 | $43 |
| Pfizer | 2 | $41 |
| Acella Pharmaceuticals, LLC | 2 | $40 |
| Ascendis Pharma Endocrinology Inc | 2 | $33 |
| Bayer | 2 | $32 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Avvisto Therapeutics, LLC | 1 | $15 |
| Merck | 1 | $12 |
How this compares
$4,357 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 130 | $184,675 |
| JardianceEmpagliflozin | 96 | $123,343 |
| Tresiba Flextouch U-100Insulin Degludec | 118 | $91,246 |
| MounjaroTirzepatide | 57 | $73,996 |
| TrulicityDulaglutide | 35 | $49,975 |
| JanuviaSitagliptin Phosphate | 35 | $40,153 |
| FarxigaDapagliflozin Propanediol | 27 | $38,781 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $36,491 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 25 | $26,929 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $20,656 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $20,452 |
| Gvoke Hypopen 2-PackGlucagon | 29 | $17,357 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $15,060 |
| Novolog FlexpenInsulin Aspart | 29 | $11,318 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $7,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $562 | $188,610141 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $371 | $125,979109 claims |
| Boehringer IngelheimJardiance | $187 | $123,34396 claims |
| MerckJanuvia | $12 | $40,15335 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $119 | $20,45213 claims |
| AbbVieSynthroid | $57 | $7,86689 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $136 | $1,419107 claims |
| PfizerLevoxyl | $41 | $69611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Frisco
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.